Clarity For Celgene On Revlimid, A Backbone Of MM Treatment
Executive Summary
Celgene reached a patent settlement with generic rival Natco that will allow entry of generic lenalidomide in March 2022, but only a limited quantity initially.
You may also be interested in...
Celgene’s Otezla Shines, On Track To Be A Fourth Blockbuster Pillar
Sales of the psoriasis drug increased 170% in the second quarter to $242m, giving the blood cancer specialist a strong anchor as it looks to expand in inflammation and immunology.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.